Risultati per: Dalla presbifagia alla sarcopenia, il trattamento in medicina generale
Questo è quello che abbiamo trovato per te
Tu1569 PREVALENCE OF SARCOPENIA AND ITS RELATED FACTORS AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA: A META-ANALYSIS
Tu1558 MODIFIED MELD 3.0 SARCOPENIA SCORES IMPROVE PREDICTIVE ACCURACY FOR OVERALL SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING LOCOREGIONAL THERAPY.
Su1712 DIAGNOSING SARCOPENIA WITH AI-AIDED ULTRASOUND (DINOSAUR) – A VALIDATION STUDY
EP85 IMPACT OF SARCOPENIA ON POST-LIVER TRANSPLANT HOSPITALIZATION DURATION: INSIGHTS FROM A SOUTH ASIAN COHORT
1226 MANAGEMENT OF SARCOPENIA IN SURGICAL PATIENTS: A MODIFIED DELPHI CONSENSUS
685 THE EFFICACY OF 12-WEEK SUPERVISED HOME-BASED EXERCISE AND BRANCHED-CHAIN AMINO ACIDS SUPPLEMENTATION FOR TREATMENT OF SARCOPENIA IN CIRRHOTIC PATIENTS: A PROSPECTIVE PILOT STUDY.
Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis
Objectives
To determine the association of non-alcoholic fatty liver disease (NAFLD) with the incidence of sarcopenia.
Design
Systematic review and meta-analysis of observational clinical studies.
Setting and participants
Adults with NAFLD.
Methods
Databases such as PubMed, Embase, Cochrane and Web of Science were searched for eligible studies published from the inception of each database up to 4 April 2023. All cross-sectional studies on the association between NAFLD and sarcopenia were included in this study. The quality of the included studies and risk of bias was assessed using the Agency for Healthcare Research and Quality checklist. STATA V.15.1 software was used for statistical analysis.
Results
Of the 1524 retrieved articles, 24 were included in this review, involving 88 609 participants. Our findings showed that the prevalence of sarcopenia was higher in the NAFLD group than in the control group (pooled OR 1.74, 95% CI 1.39 to 2.17). In a subgroup analysis by region, patients with NAFLD showed an increased risk of sarcopenia (pooled OR 1.97, 95% CI 1.54 to 2.51) in the Asian group, whereas patients with NAFLD had no statistically significant association with the risk of sarcopenia in the American and European groups, with a pooled OR of 1.31 (95% CI 0.71 to 2.40) for the American group and a pooled OR of 0.99 (95% CI 0.21 to 4.69) for the European group. Similar results were observed in the sensitivity analysis, and no evidence of publication bias was observed.
Conclusions and implications
The current study indicated a significant positive correlation between NAFLD and sarcopenia, which may be affected by regional factors. This study provides the correlation basis for the relationship between NAFLD and sarcopenia and helps to find the quality strategy of sarcopenia targeting NAFLD.
Diagnosi e trattamento della vescica iperattiva idiopatica: linea guida
Identificazione della malattia renale cronica in Medicina Generale
Stop al numero chiuso a Medicina, adottato il testo base in Senato
Marti, ‘massima convergenza’ in Commissione Istruzione al Senato
Identificazione della popolazione eleggibile alla terapia con Acido Bempedoico in medicina generale
Diagnosi, trattamento e monitoraggio dell’ADHD
Longitudinal association of sleep duration with possible sarcopenia: evidence from CHARLS
Objectives
There are limited data on the relationship between sleep duration and possible sarcopenia. Hence, this study aimed to investigate the associations of sleep duration with possible sarcopenia and its defining components based on the China Health and Retirement Longitudinal Study (CHARLS).
Design
A retrospective cohort study.
Setting
This study was conducted on participants aged over 45 years applying the 2011 baseline and 2015 follow-up survey from CHARLS covering 450 villages, 150 counties and 28 provinces.
Participants
Data from 5036 individuals (2568 men and 2468 women) free of possible sarcopenia at baseline were analysed.
Primary and secondary outcome measures
The dose-response relationship between sleep duration and possible sarcopenia.
Results
During 4 years of follow-up, 964 (19.14%) participants developed possible sarcopenia. Compared with participants who slept 6–8 hours per night, those with shorter sleep duration (8 hours per night) was not significantly associated with incident possible sarcopenia. The plots of restricted cubic splines exhibited an atypical inverse J-shaped association between sleep duration and possible sarcopenia. Subgroup analysis showed a stronger association between sleep duration and possible sarcopenia in participants aged 45–59 years and composed of male populations.
Conclusions
Short sleep duration was a potential risk factor for possible sarcopenia and low handgrip strength. The improvement of sleep duration should be considered a target in early preventive and administrative strategies against the development of handgrip strength decline and further reduced the occurrence of sarcopenia.
AI, Doria 'sfruttare la genetica per la medicina personalizzata'
Serve un sistema che integri i dati che arrivano da varie fonti